Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the ...

Based on the Phase 3 CheckMate-9DW trial, Opdivo plus Yervoy demonstrated a statistically significant overall survival benefit compared to investigator’s choice of lenvatinib or sorafenib 1 In the ...

Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy in Patients with Microsatellite ...

Opdivo is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union Approval is based on results from the Phase 3 CheckMate -67T clinical trial which demonstrated ...

Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

Approval based on results from the CheckMate-77T trial which showed perioperative Opdivo improved event-free survival compared to neoadjuvant chemotherapy and placebo followed by surgery and adjuvant ...

Based on phase 3 trial data, the FDA accepted an sBLA for nivolumab plus AVD for untreated stage III or IV classical Hodgkin lymphoma.

The product is administered over a period of 3 to 5 minutes into the subcutaneous tissue of the abdomen or thigh by a health care provider. Opdivo Qvantig combines nivolumab, a programmed death ...

Opdivo Qvantig (nivolumab/hyaluronidase-nvhy) is a prescription drug used to treat certain types of cancer. Opdivo Qvantig comes as a liquid that’s injected under your skin. Opdivo Qvantig is used in ...

Adding nivolumab (Opdivo) instead of brentuximab vedotin (Adcetris) to the standard chemotherapy backbone of doxorubicin (Adriamycin), vinblastine, and dacarbazine (AVD) resulted in longer progression ...

The Delhi High Court has allowed Zydus Lifesciences to sell its nivolumab biosimilar, citing public interest, while directing ...